{"id":449250,"date":"2021-03-03T07:03:06","date_gmt":"2021-03-03T12:03:06","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=449250"},"modified":"2021-03-03T07:03:06","modified_gmt":"2021-03-03T12:03:06","slug":"prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/","title":{"rendered":"Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WILMINGTON, Del., March  03, 2021  (GLOBE NEWSWIRE) &#8212; Prelude Therapeutics Inc. (\u201cPrelude\u201d, \u201cthe Company\u201d, \u201cwe\u201d, \u201cour\u201d) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in three upcoming virtual investor conferences:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Barclays Global Healthcare Conference<br \/><\/strong>Fireside chat at 8:35 a.m. ET on Wednesday, March 10, 2021<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Morgan Stanley Virtual Healthcare Corporate Access Day<br \/><\/strong>1&#215;1 meetings on Tuesday, March 16, 2021<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Oppenheimer 31<\/strong><br \/>\n          <sup><br \/>\n            <strong>st<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Healthcare Conference<br \/><\/strong>Corporate presentation at 3:50 p.m. ET on Wednesday, March 17, 2021<\/li>\n<\/ul>\n<p align=\"justify\">A live webcast of the Barclays fireside chat and Oppenheimer presentation can be accessed under \u201cEvents &amp; Presentations\u201d in the Investor Section of the Company\u2019s website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7fWmnEs4jZAVZyCHjU3EcJ33catdRRZRkRRFqvp220T2WpHS4DSJesNkY47iIO4IK7lSKEAZoPrZ46Q5dJwW5ZBJAV_Hf60NvyGP1VHQfj53cwf6BD7gFVUf_PPUOISjrfgiM8S6kaWZ0Yy_nvaqHlANfTBX9dIlO1lCeNz_TQpusP0xIxoYpfMh5UTywZ2a_lBGaL23WUAUhsMYI9U1lBmdEHIrXexT1g2lLPTOoGA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/investors.preludetx.com\/news-and-events\/events-and-presentations<\/a>, where a replay of the events will also be available for a limited time.<\/p>\n<p align=\"justify\">\n        <strong>About Prelude Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company\u2019s lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude\u2019s first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). The Company\u2019s pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed\/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.<\/p>\n<p>\n        <strong>Contact<\/strong>\n      <\/p>\n<p align=\"justify\">Melissa Forst<br \/>Argot Partners<br \/>212.600.1902<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UKLCwB04mPjbo3zbnxgnKGp2HT_SJ1pSCVzZjuXJP5ypxL7mJBJ1LWT0X6A79gZ13ZmsHaluNiRwvQRaqmDGRBu80fnKsQyJHGI2j59Gdsk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">prelude@argotpartners.com<\/a><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzMxMCM0MDQ1NDE4IzIyMDIzMjM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/9ee736cc-1359-40b7-b4bc-1c00a8f2b0f5\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WILMINGTON, Del., March 03, 2021 (GLOBE NEWSWIRE) &#8212; Prelude Therapeutics Inc. (\u201cPrelude\u201d, \u201cthe Company\u201d, \u201cwe\u201d, \u201cour\u201d) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in three upcoming virtual investor conferences: Barclays Global Healthcare ConferenceFireside chat at 8:35 a.m. ET on Wednesday, March 10, 2021 Morgan Stanley Virtual Healthcare Corporate Access Day1&#215;1 meetings on Tuesday, March 16, 2021 Oppenheimer 31 st Annual Healthcare ConferenceCorporate presentation at 3:50 p.m. ET on Wednesday, March 17, 2021 A live webcast of the Barclays fireside chat and Oppenheimer presentation can be accessed under \u201cEvents &amp; Presentations\u201d in the Investor Section of the Company\u2019s website, https:\/\/investors.preludetx.com\/news-and-events\/events-and-presentations, where a replay of the events will also be available for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-449250","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WILMINGTON, Del., March 03, 2021 (GLOBE NEWSWIRE) &#8212; Prelude Therapeutics Inc. (\u201cPrelude\u201d, \u201cthe Company\u201d, \u201cwe\u201d, \u201cour\u201d) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in three upcoming virtual investor conferences: Barclays Global Healthcare ConferenceFireside chat at 8:35 a.m. ET on Wednesday, March 10, 2021 Morgan Stanley Virtual Healthcare Corporate Access Day1&#215;1 meetings on Tuesday, March 16, 2021 Oppenheimer 31 st Annual Healthcare ConferenceCorporate presentation at 3:50 p.m. ET on Wednesday, March 17, 2021 A live webcast of the Barclays fireside chat and Oppenheimer presentation can be accessed under \u201cEvents &amp; Presentations\u201d in the Investor Section of the Company\u2019s website, https:\/\/investors.preludetx.com\/news-and-events\/events-and-presentations, where a replay of the events will also be available for &hellip; Continue reading &quot;Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-03T12:03:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzMxMCM0MDQ1NDE4IzIyMDIzMjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences\",\"datePublished\":\"2021-03-03T12:03:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\\\/\"},\"wordCount\":261,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MzMxMCM0MDQ1NDE4IzIyMDIzMjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\\\/\",\"name\":\"Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MzMxMCM0MDQ1NDE4IzIyMDIzMjM=\",\"datePublished\":\"2021-03-03T12:03:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MzMxMCM0MDQ1NDE4IzIyMDIzMjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MzMxMCM0MDQ1NDE4IzIyMDIzMjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences - Market Newsdesk","og_description":"WILMINGTON, Del., March 03, 2021 (GLOBE NEWSWIRE) &#8212; Prelude Therapeutics Inc. (\u201cPrelude\u201d, \u201cthe Company\u201d, \u201cwe\u201d, \u201cour\u201d) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in three upcoming virtual investor conferences: Barclays Global Healthcare ConferenceFireside chat at 8:35 a.m. ET on Wednesday, March 10, 2021 Morgan Stanley Virtual Healthcare Corporate Access Day1&#215;1 meetings on Tuesday, March 16, 2021 Oppenheimer 31 st Annual Healthcare ConferenceCorporate presentation at 3:50 p.m. ET on Wednesday, March 17, 2021 A live webcast of the Barclays fireside chat and Oppenheimer presentation can be accessed under \u201cEvents &amp; Presentations\u201d in the Investor Section of the Company\u2019s website, https:\/\/investors.preludetx.com\/news-and-events\/events-and-presentations, where a replay of the events will also be available for &hellip; Continue reading \"Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-03T12:03:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzMxMCM0MDQ1NDE4IzIyMDIzMjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences","datePublished":"2021-03-03T12:03:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/"},"wordCount":261,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzMxMCM0MDQ1NDE4IzIyMDIzMjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/","name":"Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzMxMCM0MDQ1NDE4IzIyMDIzMjM=","datePublished":"2021-03-03T12:03:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzMxMCM0MDQ1NDE4IzIyMDIzMjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzMxMCM0MDQ1NDE4IzIyMDIzMjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prelude-therapeutics-announces-participation-at-three-upcoming-virtual-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/449250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=449250"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/449250\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=449250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=449250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=449250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}